Market Access and Pricing

Qualitative study breaks down challenges and priorities of the Medicare Shared Savings Program, as noted by affordable care organizations.

Fighting for patient affordability doesn’t necessarily require a scapegoat.

Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

An MDVIP study reports that 61% of people feel hassled by the current structure.

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement, Policy Insights, Cencora, provides a look at his recent webinar focused on the implications of the Inflation Reduction Act.

A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.

A trial set out to determine whether empagliflozin can help prevent hospitalizations and extend life for patients with heart failure, while not hurting the US payers’ pockets.

The lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.

Technavio analysis notes that an increase drug patent expirations could be a contributing factor.

Cohort study dives into whether low income subsidy losses are associated with disability status, age, and race and ethnicity.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

And the need to boost awareness of this critical healthcare resource.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

In order to provide both profitability and medication access, a balancing act is required.

Duplicate rebates have resulted in revenue leakage for manufacturers.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.